血清细胞角蛋白 19 片段：晚期甲状腺癌的去分化标志物。
Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer.
机构信息
Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Via Ospedale 12, CH-6500 Bellinzona, Switzerland.
出版信息
Eur J Endocrinol. 2012 Dec;167(6):793-7. doi: 10.1530/EJE-12-0660. Epub 2012 Sep 18.
BACKGROUND
This study was undertaken to evaluate serum cytokeratin 19 fragment (Cyfra 21.1) expressions in patients with advanced thyroid carcinoma and to explore the relationship between serum Cyfra 21.1 and the degree of radioiodine ((131)I) avidity of thyroid carcinoma cells.
METHODS
Enrolled were 76 consecutive patients with advanced thyroid carcinoma submitted to high-activity (131)I treatment. In each patient, serum thyroglobulin (Tg) and Cyfra 21.1 were measured before (131)I administration and compared with the posttreatment whole-body scan results.
RESULTS
Thirty-one (41%) of 76 patients had iodine-avid and 45 (59%) had iodine-refractory diseases respectively. Significantly higher serum Cyfra 21.1, but not Tg, levels were found in patients with (131)I-refractory disease compared with patients with iodine-avid disease (P<0.01).
CONCLUSIONS
This is the first report describing the potential role of serum Cyfra 21.1 as marker of dedifferentiation and resistance to (131)I therapy in patients with advanced thyroid carcinoma.
背景
本研究旨在评估晚期甲状腺癌患者血清细胞角蛋白 19 片段（Cyfra 21.1）的表达，并探讨血清 Cyfra 21.1 与甲状腺癌细胞对放射性碘 ((131)I) 摄取程度的关系。
方法
纳入 76 例连续接受高活性 (131)I 治疗的晚期甲状腺癌患者。在每位患者中，在 (131)I 给药前测量血清甲状腺球蛋白 (Tg) 和 Cyfra 21.1，并将其与治疗后的全身扫描结果进行比较。
结果
76 例患者中，31 例（41%）为碘有效，45 例（59%）为碘无效。与碘有效疾病患者相比，(131)I 无效疾病患者的血清 Cyfra 21.1 水平显著升高，但 Tg 水平无显著差异（P<0.01）。
结论
这是第一篇描述晚期甲状腺癌患者血清 Cyfra 21.1 作为分化降低和对 (131)I 治疗耐药的标志物的潜在作用的报告。
Zotero 插件